Wu Liuli, Huang Junchao, Jia Xiongfei, Mao Xiaoqin
Department of Clinical Laboratory, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650500, People's Republic of China.
Department of Clinical Laboratory, Yunnan New Kunhua Hospital, Kunming, Yunnan, 650000, People's Republic of China.
J Inflamm Res. 2025 Feb 21;18:2677-2698. doi: 10.2147/JIR.S495987. eCollection 2025.
To investigate the role of mitochondrial ribosomal proteins (MRPs) in the pathogenesis and progression of septic myocardial injury. Additionally, we aim to propose new technical strategies and experimental foundations for the prevention and treatment of septic myocardial injury.
Animal and cell models of septic myocardial injury were established. Aberrantly expressed MRPs were screened using transcriptome sequencing, and their expression was verified by RT-qPCR and Western blot. Subsequently, overexpressed and knockdown cell models of myocardial injury were constructed. The effects on CO I, PGC-1α, ATP content, ROS fluorescence intensity, mitochondrial membrane potential, and GSDMD were assessed, along with changes in caspase-4 and IL-1β expression levels.
Transcriptome sequencing revealed a reduction in MRPs expression in mice with septic myocardial injury. Both RT-qPCR and Western blot analysis confirmed the decreased expression of MRPs in animal and cell models of septic myocardial injury. Furthermore, overexpression of both MRPS16 and MRPL47 mitigated the decrease in CO I and PGC-1α levels induced by septic myocardial injury. Additionally, overexpression of MRPS16 and MRPL47 alleviated the elevated levels of IL-1β, caspase-4, and GSDMD caused by septic myocardial injury.
The findings suggest that both MRPS16 and MRPL47 can mitigate mitochondrial injury by attenuating mitochondrial biosynthesis dysfunction, energy metabolism disorders, and Ca disturbances caused by septic myocardial injury. This ultimately reduces cellular damage and alleviates septic myocardial injury.
探讨线粒体核糖体蛋白(MRPs)在脓毒症心肌损伤发病机制及进展中的作用。此外,我们旨在为脓毒症心肌损伤的预防和治疗提出新的技术策略和实验依据。
建立脓毒症心肌损伤的动物和细胞模型。利用转录组测序筛选异常表达的MRPs,并通过RT-qPCR和蛋白质免疫印迹法验证其表达。随后,构建心肌损伤的过表达和敲低细胞模型。评估其对细胞色素C氧化酶I(CO I)、过氧化物酶体增殖物激活受体γ共激活因子1α(PGC-1α)、三磷酸腺苷(ATP)含量、活性氧(ROS)荧光强度、线粒体膜电位和Gasdermin D(GSDMD)的影响,以及半胱天冬酶-4(caspase-4)和白细胞介素-1β(IL-1β)表达水平的变化。
转录组测序显示脓毒症心肌损伤小鼠中MRPs表达降低。RT-qPCR和蛋白质免疫印迹分析均证实脓毒症心肌损伤动物和细胞模型中MRPs表达下降。此外,MRPS16和MRPL47的过表达减轻了脓毒症心肌损伤诱导的CO I和PGC-1α水平的降低。此外,MRPS16和MRPL47的过表达减轻了脓毒症心肌损伤引起的IL-1β、caspase-4和GSDMD水平的升高。
研究结果表明,MRPS16和MRPL47均可通过减轻脓毒症心肌损伤引起的线粒体生物合成功能障碍、能量代谢紊乱和钙紊乱来减轻线粒体损伤。这最终减少细胞损伤,减轻脓毒症心肌损伤。